Literature DB >> 11592526

Apoptosis and anti-apoptosis signalling in glaucomatous retinopathy.

W G Tatton1, R M Chalmers-Redman, N A Tatton.   

Abstract

PURPOSE: Recent studies in the post-mortem human retina have suggested that apoptosis contributes to retinal ganglion cell (RGC) loss in glaucoma. If apoptosis contributes significantly to glaucomatous RGC loss, and if the specific apoptosis signalling pathways for glaucomatous apoptosis can be determined, agents that interrupt or oppose the signalling have the potential to slow the progression of glaucoma.
METHODS: Recent data in animal models indicate that mitochondrially-dependent apoptosis contributes to RGC loss in glaucoma. Mitochondrially-dependent apoptosis involves proteins like BAX that increase mitochondrial membrane permeability and promote apoptosis and proteins like BCL-2 that decrease mitochondrial membrane permeability and reduce apoptosis. New protein synthesis induced by the alpha-2 agonist, brimonidine, prevents decreases in the levels of BCL-2 and thereby reduces mitochondrially-dependent apoptosis.
CONCLUSIONS: Brimonidine appears to maintain BCL-2 levels by supporting the activity of an intrinsic anti-apoptosis signalling system that involves phosphorylation of protein kinase B. Phosphorylated protein kinase B appears to counteract the apoptosis signalling mechanisms which operate in glaucomatous retina.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11592526

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  14 in total

Review 1.  Neurodegeneration in glaucoma: progression and calcium-dependent intracellular mechanisms.

Authors:  S D Crish; D J Calkins
Journal:  Neuroscience       Date:  2010-12-25       Impact factor: 3.590

2.  Brimonidine Can Prevent In Vitro Hydroquinone Damage on Retinal Pigment Epithelium Cells and Retinal Müller Cells.

Authors:  Claudio Ramírez; Javier Cáceres-del-Carpio; Justin Chu; Joshua Chu; M Tarek Moustafa; Marilyn Chwa; G Astrid Limb; Baruch D Kuppermann; M Cristina Kenney
Journal:  J Ocul Pharmacol Ther       Date:  2015-12-01       Impact factor: 2.671

Review 3.  [Mechanisms of neuroprotection against glaucoma].

Authors:  T Mittag; K-G Schmidt
Journal:  Ophthalmologe       Date:  2004-11       Impact factor: 1.059

4.  Brimonidine is neuroprotective against glutamate-induced neurotoxicity, oxidative stress, and hypoxia in purified rat retinal ganglion cells.

Authors:  Kelvin Yoon Chiang Lee; Mao Nakayama; Makoto Aihara; Yi-Ning Chen; Makoto Araie
Journal:  Mol Vis       Date:  2010-02-17       Impact factor: 2.367

5.  Brimonidine Protects Auditory Hair Cells from in vitro-Induced Toxicity of Gentamicin.

Authors:  Maurizio Cortada; Soledad Levano; Daniel Bodmer
Journal:  Audiol Neurootol       Date:  2017-09-09       Impact factor: 1.854

6.  Systemic Administration of an Apelin Receptor Agonist Prevents NMDA-Induced Loss of Retinal Neuronal Cells in Mice.

Authors:  Fumiya Shibagaki; Yuki Ishimaru; Akihide Sumino; Akiko Yamamuro; Yasuhiro Yoshioka; Sadaaki Maeda
Journal:  Neurochem Res       Date:  2020-01-01       Impact factor: 3.996

Review 7.  Neuroprotection in glaucoma.

Authors:  C R Vishwaraj; Srinivasan Kavitha; Rengaraj Venkatesh; Aakriti Garg Shukla; Premanand Chandran; Shweta Tripathi
Journal:  Indian J Ophthalmol       Date:  2022-02       Impact factor: 2.969

Review 8.  Multifaceted role of matrix metalloproteinases (MMPs).

Authors:  Divya Singh; Sanjeev K Srivastava; Tapas K Chaudhuri; Ghanshyam Upadhyay
Journal:  Front Mol Biosci       Date:  2015-05-13

9.  Susceptibility to neurodegeneration in a glaucoma is modified by Bax gene dosage.

Authors:  Richard T Libby; Yan Li; Olga V Savinova; Joseph Barter; Richard S Smith; Robert W Nickells; Simon W M John
Journal:  PLoS Genet       Date:  2005-07-25       Impact factor: 5.917

Review 10.  New trends in glaucoma risk, diagnosis & management.

Authors:  Thomas Kersey; Colin I Clement; Phillip Bloom; M Francesca Cordeiro
Journal:  Indian J Med Res       Date:  2013-04       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.